
Browsing restrictions can be lifted for a fee.
Lotus Pharmaceutical Co., Ltd. research, develops, manufactures, and sells generic pharmaceutical products in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it engages in wholesale of cosmetics; retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited.
1795
美時
-4.10%
(-0.04)
The most recent financial report for 美時 (1795) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1795's short-term business performance and financial health. For the latest updates on 1795's earnings releases, visit this page regularly.
According to historical valuation range analysis, 美時 (1795)'s current price-to-earnings (P/E) ratio is 12.94, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 美時 (1795) reported an Operating Profit of 1.19B with an Operating Margin of 25% this period, representing a decline of 43.53% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 美時 (1795) announced revenue of 4.77B, with a Year-Over-Year growth rate of -8.86%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 美時 (1795) held Total Cash and Cash Equivalents of 5.67B, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 美時 (1795) achieved the “three margins increasing” benchmark, with a gross margin of 57.32%%, operating margin of 25%%, and net margin of 30.07%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1795's profit trajectory and future growth potential.
According to the past four quarterly reports, 美時 (1795)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 5.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
美時 (1795)'s Free Cash Flow (FCF) for the period is -104.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1,740.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.